Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ponatinib as Second Line Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib, Dasatinib or Nilotinib

Trial Profile

Ponatinib as Second Line Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib, Dasatinib or Nilotinib

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 May 2019

At a glance

  • Drugs Ponatinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 May 2019 Planned End Date changed from 31 Jan 2019 to 31 Dec 2030.
    • 07 May 2019 Planned primary completion date changed from 31 Jan 2019 to 31 Dec 2030.
    • 17 Oct 2018 Planned End Date changed from 1 Jan 2019 to 31 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top